BioCryst de­buts print mag­a­zine for hered­i­tary an­gioede­ma pa­tients tak­ing Or­ladeyo

BioCryst Phar­ma­ceu­ti­cals is go­ing old school with a print mag­a­zine sent in the mail for peo­ple tak­ing its hered­i­tary an­gioede­ma (HAE) drug, Or­ladeyo. In its de­but, the cus­tom mag­a­zine, “In­to the Blue,” in­cludes ar­ti­cles writ­ten by doc­tors, pa­tient pro­files and quotes, up­com­ing HAE-re­lat­ed events and even a cross­word puz­zle.

BioCryst likened the mag­a­zine to oth­er com­mon com­mu­ni­ty-fo­cused pub­li­ca­tions, such as ones for new moth­ers. In this case, the goal is to en­gage peo­ple around the com­mon bond of hav­ing an HAE di­ag­no­sis and tak­ing Or­ladeyo. HAE is a rare hered­i­tary and het­ero­ge­neous dis­ease with vary­ing fac­tors, in­clud­ing age of on­set, symp­toms and pa­tient pop­u­la­tion de­mo­graph­ics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER